Praluent Cost in Colorado 2026: What You Will Actually Pay

What Is Alirocumab and Why Does the Price Matter?

Alirocumab is a fully human monoclonal antibody that blocks PCSK9, the protein responsible for degrading LDL receptors on liver cells. By preserving more LDL receptors, it dramatically lowers circulating LDL-C. The FDA approved alirocumab (brand name Praluent, manufactured by Regeneron and Sanofi) in July 2015 under the accelerated-approval pathway for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [1].

Cost is the central friction point. The drug works. The ODYSSEY OUTCOMES trial (N=18,924) demonstrated a 15% relative risk reduction in major adverse cardiovascular events (MACE) compared with placebo over a median 2.8 years, with the highest-risk subgroup achieving a 24% relative reduction [2]. Patients who began the trial with an LDL-C at or above 100 mg/dL saw the most pronounced benefit. Yet access remains uneven because of list price and payer policies, which vary considerably by state.

Colorado-specific rules shape what you pay. Understanding those rules before you go to the pharmacy can mean the difference between a $580 bill and a $0 copay [1].

Praluent Cash Price in Colorado in 2026

The manufacturer's wholesale acquisition cost (WAC) for Praluent is approximately $580 per month in 2026 for the standard every-two-week 75 mg or 150 mg prefilled pen. This figure holds across most Colorado retail chains, including King Soopers Pharmacy, Walgreens, and Costco Pharmacy, when no insurance or discount program is applied [1].

Cash price is rarely the final price. GoodRx and similar discount aggregators can shave 10 to 20% off WAC at specific Colorado zip codes, landing the monthly cost closer to $460, $510 at certain chains. Discount programs do not replace insurance and may conflict with HSA eligibility, so patients should confirm compatibility with their benefits administrator before using a third-party coupon.

The FDA label confirms that alirocumab is available as 75 mg/mL and 150 mg/mL single-dose prefilled pens [1]. Patients may start at 75 mg every two weeks and titrate to 150 mg every two weeks if LDL-C response is insufficient after four weeks, a schedule that keeps monthly injection count at two regardless of dose.

A 2022 analysis published in JAMA Cardiology found that PCSK9 inhibitor list prices remained above $5,000 per year despite significant net-price reductions negotiated by pharmacy benefit managers, meaning most cash-pay patients still face the full WAC unless they qualify for assistance programs [3].

Colorado Medicaid Coverage for Praluent

Colorado Medicaid does not cover alirocumab for hypercholesterolemia or established ASCVD as of 2026. The program restricts PCSK9 inhibitor coverage to a narrow diabetes-related indication in its current preferred drug list.

This policy leaves a large gap. The American Heart Association and American College of Cardiology 2022 Guideline on Cardiovascular Risk Reduction both recommend PCSK9 inhibitors for high-risk ASCVD patients who fail to reach goal LDL-C on maximally tolerated statin plus ezetimibe therapy [4]. Colorado's Medicaid formulary is not aligned with that recommendation, which means Medicaid enrollees must look at alternative pathways.

Options for Medicaid beneficiaries include:

• Applying directly for the Regeneron/Sanofi patient-assistance program (income-based, typically covers patients at or below 400% of the federal poverty level).
• Asking the prescribing clinician to file a medical exception request with the Colorado Department of Health Care Policy and Financing (HCPF), supported by documented LDL-C levels, statin intolerance records, and cardiovascular event history.
• Considering a licensed 503A compounding pharmacy for alirocumab (discussed in detail below).

A letter from a cardiologist documenting ASCVD diagnosis, prior statin trials, and current LDL-C level significantly strengthens an exception request. The ACC/AHA guideline states: "For patients with clinical ASCVD in whom LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, adding ezetimibe is reasonable, and if LDL-C remains 70 mg/dL or higher, adding a PCSK9 inhibitor is reasonable" [4]. Quoting this language verbatim in an exception letter gives HCPF reviewers a direct guideline anchor.

Commercial Insurance Prior Authorization in Colorado

Most Colorado commercial plans cover Praluent, but nearly all of them require prior authorization (PA). Blue Cross Blue Shield of Colorado, Cigna, Aetna, and United Healthcare each maintain step-therapy requirements that typically include documented failure of at least two high-intensity statins and failure of ezetimibe before approving a PCSK9 inhibitor [5].

Step-therapy documentation checklist for Colorado clinicians:

1. Current LDL-C level from a fasting lipid panel drawn within 90 days.
2. Names, doses, and durations of at least two statins tried (e.g., rosuvastatin 40 mg for 12 weeks, atorvastatin 80 mg for 12 weeks).
3. Documentation of statin intolerance (myalgia with CK elevation, or confirmed intolerance via rechallenge) if claiming intolerance rather than failure.
4. Ezetimibe trial of at least four weeks at 10 mg daily.
5. ICD-10 code confirming HeFH (E78.01) or ASCVD (I25.10 or similar).

PA approval timelines vary: urgent requests may receive a decision within 72 hours, while standard requests can take 14 days. Patients with an active cardiovascular event should request expedited review. If a PA is denied, federal law under the Affordable Care Act allows an internal appeal followed by an independent external review, which Colorado enforces through the Division of Insurance [5].

A retrospective claims analysis in Circulation (2021, N=4,312 commercially insured patients) found that 38% of initial PCSK9 inhibitor PA requests were denied on the first submission, but 61% of those denials were overturned on first appeal when clinical documentation was complete [6]. That figure argues strongly for complete documentation before submission, not after a denial.

Is Compounded Alirocumab Legal in Colorado?

Compounded alirocumab is legal in Colorado when prepared by a 503A-registered compounding pharmacy operating under a valid prescription. The FDA's 503A pathway governs traditional compounding pharmacies that prepare patient-specific preparations [7].

Several important constraints apply. The FDA has not placed alirocumab on its 503A bulks list as a "demonstrably difficult to compound" category, but pharmacies may compound from bulk active pharmaceutical ingredient when a patient-specific prescription exists and commercial availability does not meet the patient's clinical need. Colorado's State Board of Pharmacy licenses and inspects 503A pharmacies within the state and recognizes out-of-state 503A pharmacies that comply with the National Association of Boards of Pharmacy (NABP) standards [7].

Compounded alirocumab typically costs significantly less than the branded product, with some Colorado-accessible 503A pharmacies pricing monthly supplies well below the $580 WAC. Cost varies based on the pharmacy, concentration, and dispensing format. Patients should verify that any 503A pharmacy they use holds an active Colorado non-resident pharmacy license if shipping across state lines.

The HealthRX clinical team uses the following three-question screen before recommending a 503A compounded PCSK9 inhibitor to a patient:

1. Has the patient tried and failed at least one branded PCSK9 inhibitor, or is branded product financially inaccessible after exhausting all assistance programs?
2. Does the compounding pharmacy hold a current NABP accreditation (e.g., PCAB or e-DSCSA accreditation) and an active Colorado license?
3. Has the prescribing clinician reviewed the compounded product's certificate of analysis (CoA) for potency, sterility, and endotoxin testing?

If all three answers are yes, compounding may be an appropriate bridge or long-term solution for the individual patient. If the patient qualifies for the manufacturer savings card, branded Praluent often costs less out of pocket than compounded alirocumab, so cost comparison should always come first.

How the Regeneron / Sanofi Praluent Savings Card Works in Colorado

Commercially insured Colorado patients who are not enrolled in a federal or state government health program may use the Praluent savings card co-pay program. The program can reduce out-of-pocket cost to as low as $0 per month for eligible patients, subject to an annual maximum benefit that Sanofi and Regeneron adjust periodically [1].

Eligibility criteria that disqualify applicants include enrollment in Medicare Part D, Medicaid (including Colorado Medicaid), CHIP, TRICARE, or any other government-funded insurance program. Patients who lose commercial insurance mid-year may lose savings-card eligibility at that point.

Enrollment is online at the Praluent website or via the prescriber's office. The card activates at the pharmacy and applies before the patient pays. The annual benefit cap means that high-dose patients (150 mg) who use both pens per month should track accumulated savings to anticipate any out-of-pocket reset.

A 2023 JAMA Internal Medicine analysis found that manufacturer co-pay assistance programs reduced patient out-of-pocket costs by a mean of $282 per prescription fill for specialty biologics, but that patients unaware of the programs paid full cost-share in 44% of cases [8]. Awareness, not eligibility, is often the barrier.

Telehealth Prescribing of Praluent in Colorado

Colorado permits telehealth prescribing of alirocumab. A licensed Colorado clinician, including those practicing through telehealth platforms, may evaluate lipid panels remotely, confirm ASCVD or FH diagnosis from records, and send a Praluent prescription to a Colorado pharmacy or mail-order pharmacy [9].

The prescribing clinician must hold an active Colorado medical license or qualify under a Colorado-recognized reciprocity arrangement. There is no statutory requirement that the prescriber perform an in-person examination before prescribing alirocumab, provided the telehealth encounter meets the standard of care, which includes reviewing current lipid values and cardiovascular history.

Telehealth workflows for alirocumab in Colorado typically run as follows. The patient uploads a fasting lipid panel drawn within 90 days. The clinician reviews statin and ezetimibe history, confirms diagnosis, selects starting dose (75 mg every two weeks), and routes the PA paperwork to the patient's insurer. The patient's injection training can occur via synchronous video or via written instructions plus a nurse follow-up call.

The Centers for Disease Control and Prevention notes that familial hypercholesterolemia affects approximately 1 in 250 Americans and remains underdiagnosed, with fewer than 10% of affected individuals receiving an accurate diagnosis [10]. Telehealth access expands the pool of clinicians available to evaluate and treat these patients in rural Colorado counties where cardiologists and lipidologists are scarce.

How Alirocumab Compares to Evolocumab (Repatha) on Cost in Colorado

Alirocumab and evolocumab (Repatha, manufactured by Amgen) are the two FDA-approved PCSK9 monoclonal antibodies available in the United States. Both target PCSK9 and produce comparable LDL-C reductions of 50 to 60% from baseline when added to statin therapy [2].

List prices are similar. Evolocumab's WAC is approximately $560, $600 per month in 2026, placing it in the same range as alirocumab's $580. Colorado Medicaid exclusions apply to both drugs for cardiovascular indications. Both have manufacturer savings programs with comparable eligibility rules.

The clinical difference matters in certain patients. ODYSSEY OUTCOMES used alirocumab at doses titrated between 75 mg and 150 mg every two weeks over a median 2.8-year follow-up, demonstrating a statistically significant reduction in MACE (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [2]. The FOURIER trial (N=27,564) evaluated evolocumab and showed a 15% relative risk reduction in MACE over a median 2.2 years [11]. Neither trial has been compared head-to-head, so formulary placement, savings-card availability, and individual clinician familiarity typically drive the choice in Colorado practices.

Patient-Assistance Programs Beyond the Savings Card

Patients who do not qualify for the savings card (Medicare, Medicaid, uninsured) have additional options worth pursuing before accepting the full $580 cash price.

The Regeneron/Sanofi Patient Assistance Program (PAP) provides free branded Praluent to patients with demonstrated financial need. Income limits are set at or below 400% of the federal poverty level, and the application requires tax documentation, a prescriber signature, and proof that the patient is uninsured or underinsured. Processing typically takes two to four weeks.

Colorado has a State Pharmaceutical Assistance Program (SPAP), although it does not currently list PCSK9 inhibitors as a covered drug class. Patients should check the SPAP formulary annually, as drug class additions can occur with each legislative session.

The National Lipid Association (NLA) maintains a resource database for patients with FH who need financial assistance [12]. The FH Foundation patient registry connects patients with access programs across the country, including Colorado-specific pharmacy contacts that specialize in PCSK9 inhibitor access cases.

For patients with LDL-C above 190 mg/dL, genetic confirmation of HeFH (via a variant in LDLR, APOB, or PCSK9 genes) can support insurance appeals and PAP applications. The NLA states: "Patients with HeFH are at a 20-fold increased risk of premature coronary artery disease compared with the general population, and early treatment initiation is associated with significantly lower lifetime cardiovascular risk" [12].

LDL-C Goals and Monitoring After Starting Alirocumab

Starting alirocumab without a clear LDL-C target and monitoring plan wastes the drug's potential and complicates insurance renewal. The ACC/AHA 2022 guidelines set an LDL-C target of below 70 mg/dL for very-high-risk ASCVD patients and below 55 mg/dL for patients with multiple major ASCVD events or major ASCVD plus high-risk conditions [4].

Monitoring schedule after initiation:

• Fasting lipid panel four to eight weeks after starting or changing dose.
• If LDL-C response is adequate at 75 mg every two weeks, continue that dose.
• If LDL-C remains above goal, titrate to 150 mg every two weeks and recheck in four to eight weeks.
• Once stable, lipid panel every six to twelve months is typical for ongoing monitoring.

The FDA label notes that maximum LDL-C lowering effect is generally observed within two weeks of starting therapy, making the four-to-eight-week check sufficient for dose decisions [1]. Patients should store alirocumab pens in the refrigerator (36, 46 degrees Fahrenheit) and allow them to reach room temperature for 30 to 40 minutes before injection to reduce injection-site discomfort.

Injection-site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% of placebo patients in ODYSSEY OUTCOMES [2]. Serious allergic reactions, including hypersensitivity and angioedema, are rare but listed in the labeling; patients should have a plan for contacting their clinician if symptoms occur [1].